This just in from the OHSU Office of Proposal and Award Management: effective Monday, December 15th, if a proposal includes key personnel from a different department with at least 5% effort, it can be routed as Information Only to the key person, their department chair or unit head, and their dean or director. This is a significant change to the previous requirement to route the proposal for Approval. The Information Only route will notify individuals … Read More
The Office of Research on Women’s Health (ORWH) has announced the availability of administrative supplements to NIH-funded researchers to encourage the consideration of sex/gender factors in their ongoing research. If you currently have NIH funding under one of the following mechanisms, you may be eligible : P01, P20, P30, P50, P60, PM1, U10, U19, U54, U56, UM1, DP!, DP2, DP3, DP4, DP5/UP5, RM1, R01, R15, R37, and U01. The proposed research must address at least one objective from Goals … Read More
While you were enjoying your holidays, Sally Rockey announced last week that the NIH really, truly is implementing the new 5-page biosketch format with the annotated bibliography section detailing the importance of your contributions to science. This format applies to projects beginning in 2016, but that means applications with due dates as early as January 2015–so it’s not too soon to start preparing. This change will require you to spend some time thinking about, rewriting, … Read More
Joe Gray, Ph.D., associate director of translational research for the Knight Cancer Institute and director of the Center for Spatial Systems Biomedicine, will join Knight Cancer Institute researcher Summer Gibbs, Ph.D., assistant professor in the department of biomedical engineering, and Joseph Carroll, Ph.D., director of business development for the Knight Cancer Institute, to discuss how multi-institution, public-private partnerships are being developed and how they are advancing the research of complex biological systems. Tuesday, Nov. 11 7:30 p.m. … Read More
A new study recently published in Nature identifies a method for site-specific gene addition that may reduce adverse effects and lead to safe and more effective gene targeting. The study, conducted by researchers at Stanford and UCSF, was performed on mice with hemophilia B and demonstrated reduced bleeding in the mice and minimal side effects typically associated with other gene addition methods.
Recent advances in imaging technology allow researchers to capture snapshots of embryonic cells as they divide and migrate through development. But capturing an image of a growing embryo every 30 seconds or so, produces terabytes of data that is time consuming to analyze. A team led by HHMI, Janelia Group Leader, Philipp Keller, Ph.D., has created a piece of software that identifies and tracks dividing cells as quickly as high-speed microscopes can collect the images. … Read More
The “Dance your Ph.D.” contest challenges scientists around the world to explain their Ph.D. research without a PowerPoint or jargon–in fact, no talking at all. So if you’re tired of trying to explain what your Ph.D. research is about to friends and relatives, only to have their eyes glaze over, this contest may be for you! Winners of the 7th annual contest sponsored by Science, AAAS (publisher of Science), and HighWire Press, were announced November … Read More
Karl R. Koehler, Ph.D., will give a lecture titled “Modeling Inner Ear Organogenesis with Stem Cells,” sponsored by the Oregon Hearing Research Center. Dr. Koehler is a postdoctoral fellow at Indiana University School of Medicine in the department of Otolaryngology-Head and Neck Surgery. His paper, “Generation of inner ear sensory epithelia from pluripotent stem cells in 3D culture,” was published in Nature in 2013. Friday, Oct. 31, 4 p.m., Vollum M1441. You can read more … Read More
Did you know that the NIH Common Fund was holding a video competition to commemorate its 10-year anniversary? Neither did we, but after seeing this Common Fund rap, we will definitely be going with the Common Fund.
Jay Nelson, director of the OHSU Vaccine & Gene Therapy Institute, has been awarded a $10 million contract from the National Institutes of Health for discovery work on new ways to improve vaccines. They were one of seven groups awarded such contracts. Vaccine adjuvants are compounds that bolster the innate immune response, essentially super-charging the vaccine. While adjuvants show great promise in improving vaccines and fighting disease, currently just three are in use–scientists at VGTI … Read More